NVAX's COVID-flu combo shot sparks strong immunity in seniors, fueling plans for further late-stage trials.

Shares of Moderna MRNA declined nearly 8% yesterday after it announced that it had voluntarily withdrawn a regulatory filing seeking the FDA’s approval for mRNA-1083, its investigational mRNA ...

Novavax (NVAX) stock gains as the company reports promising Phase 3 trial results for its COVID-19-Influenza combo vaccine and stand-alone flu shot. Read more here.

The Food and Drug Administration has issued a long-awaited approval of Novavax’s COVID-19 vaccine but with unusual restrictions.

Covid shots are facing greater scrutiny from top federal health officials like RFK Jr. and the FDA's Marty Makary.

The Food and Drug Administration gave Covid vaccine manufacturers instructions on what next fall’s Covid vaccines should target on Thursday, signaling it would prefer that they update the strain ...

The Trump administration's effort to impose new requirements on Novavax's COVID-19 vaccine is sowing uncertainty about other vaccines, too.

Moderna's voluntary withdrawal of the filing stems from the FDA's request for vaccine efficacy data from a phase III study on the experimental flu shot.

Novavax said Monday that the Food and Drug Administration was asking the company to run a new clinical trial of its vaccine.